Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Urologic Neoplasms

ClinicalTrials.gov lists 4,333 trials for Urologic Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 231.

MeSH D014571 Neoplasms Neoplasm C04 C12
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 771 Phase 1/2 Phase 1/2 374 Phase 2 Phase 2 1,125 Phase 2/3 Phase 2/3 34 Phase 3 Phase 3 312 Phase 4 Phase 4 72 Not applicable Not applicable 727 Observational Observational 902 Phase 1 Phase 1 771 Phase 1/2 Phase 1/2 374 Phase 2 Phase 2 1,125 Phase 2/3 Phase 2/3 34 Phase 3 Phase 3 312 Phase 4 Phase 4 72 Not applicable Not applicable 727 Observational Observational 902

Trials per phase (log scale)

1 more section with rows

154 of the 4,333 trials are tagged with Urologic Neoplasms itself; the rest are tagged with a narrower condition beneath it.

Get the Urologic Neoplasms report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Urologic Neoplasms trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 11 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 270

1990: 3 trials (Observational 1, Not applicable 1, Phase 2 1) 1991: 3 trials (Phase 3 2, Phase 2 1) 1992: 3 trials (Phase 3 1, Phase 2 1, Phase 1 1) 1993: 3 trials (Observational 1, Phase 3 1, Phase 2/3 1) 1994: 10 trials (Observational 1, Phase 3 3, Phase 2/3 1, Phase 2 1, Phase 1 4) 1995: 7 trials (Phase 3 2, Phase 2/3 1, Phase 2 4) 1996: 15 trials (Phase 3 4, Phase 2 7, Phase 1/2 2, Phase 1 2) 1997: 21 trials (Observational 3, Not applicable 1, Phase 3 3, Phase 2 5, Phase 1/2 2, Phase 1 7) 1998: 36 trials (Observational 4, Phase 3 6, Phase 2 19, Phase 1/2 2, Phase 1 5) 1999: 36 trials (Observational 4, Not applicable 1, Phase 3 8, Phase 2 14, Phase 1/2 2, Phase 1 7) 2000: 57 trials (Observational 5, Not applicable 1, Phase 4 1, Phase 3 6, Phase 2/3 1, Phase 2 23, Phase 1/2 7, Phase 1 13) 2001: 56 trials (Observational 2, Not applicable 2, Phase 3 6, Phase 2/3 1, Phase 2 27, Phase 1/2 5, Phase 1 13) 2002: 47 trials (Observational 6, Not applicable 2, Phase 3 5, Phase 2 24, Phase 1/2 4, Phase 1 6) 2003: 58 trials (Observational 5, Not applicable 5, Phase 3 3, Phase 2 35, Phase 1/2 3, Phase 1 7) 2004: 86 trials (Observational 10, Not applicable 4, Phase 4 1, Phase 3 7, Phase 2/3 1, Phase 2 40, Phase 1/2 10, Phase 1 13) 2005: 99 trials (Other 1, Observational 14, Not applicable 8, Phase 3 10, Phase 2/3 1, Phase 2 36, Phase 1/2 12, Phase 1 17) 2006: 109 trials (Observational 4, Not applicable 6, Phase 4 3, Phase 3 6, Phase 2/3 1, Phase 2 48, Phase 1/2 12, Phase 1 29) 2007: 124 trials (Observational 15, Not applicable 13, Phase 4 2, Phase 3 13, Phase 2/3 2, Phase 2 52, Phase 1/2 4, Phase 1 23) 2008: 137 trials (Observational 38, Not applicable 10, Phase 4 5, Phase 3 6, Phase 2 47, Phase 1/2 8, Phase 1 23) 2009: 124 trials (Observational 29, Not applicable 12, Phase 4 1, Phase 3 10, Phase 2/3 2, Phase 2 36, Phase 1/2 9, Phase 1 25) 2010: 117 trials (Observational 26, Not applicable 8, Phase 4 1, Phase 3 11, Phase 2 29, Phase 1/2 14, Phase 1 28) 2011: 112 trials (Observational 23, Not applicable 13, Phase 4 4, Phase 3 7, Phase 2/3 1, Phase 2 37, Phase 1/2 6, Phase 1 21) 2012: 127 trials (Other 1, Observational 26, Not applicable 22, Phase 4 3, Phase 3 11, Phase 2/3 1, Phase 2 30, Phase 1/2 8, Phase 1 25) 2013: 109 trials (Other 1, Observational 22, Not applicable 27, Phase 4 3, Phase 3 4, Phase 2/3 3, Phase 2 21, Phase 1/2 10, Phase 1 18) 2014: 139 trials (Observational 34, Not applicable 36, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 30, Phase 1/2 12, Phase 1 20) 2015: 145 trials (Observational 28, Not applicable 34, Phase 4 4, Phase 3 7, Phase 2/3 2, Phase 2 28, Phase 1/2 14, Phase 1 28) 2016: 195 trials (Observational 41, Not applicable 35, Phase 4 2, Phase 3 14, Phase 2 40, Phase 1/2 20, Phase 1 43) 2017: 197 trials (Observational 35, Not applicable 33, Phase 4 11, Phase 3 16, Phase 2/3 1, Phase 2 51, Phase 1/2 20, Phase 1 30) 2018: 203 trials (Observational 38, Not applicable 42, Phase 4 3, Phase 3 11, Phase 2/3 2, Phase 2 58, Phase 1/2 18, Phase 1 31) 2019: 216 trials (Observational 62, Not applicable 33, Phase 4 6, Phase 3 17, Phase 2 38, Phase 1/2 19, Phase 1 41) 2020: 241 trials (Observational 75, Not applicable 43, Phase 4 2, Phase 3 9, Phase 2 51, Phase 1/2 13, Phase 1 48) 2021: 259 trials (Observational 73, Not applicable 49, Phase 4 2, Phase 3 19, Phase 2 43, Phase 1/2 34, Phase 1 39) 2022: 229 trials (Observational 67, Not applicable 47, Phase 4 2, Phase 3 10, Phase 2 43, Phase 1/2 20, Phase 1 40) 2023: 270 trials (Observational 62, Not applicable 68, Phase 4 3, Phase 3 15, Phase 2/3 2, Phase 2 48, Phase 1/2 24, Phase 1 48) 2024: 222 trials (Observational 51, Not applicable 58, Phase 4 3, Phase 3 13, Phase 2/3 2, Phase 2 37, Phase 1/2 21, Phase 1 37) 2025: 259 trials (Observational 60, Not applicable 62, Phase 4 6, Phase 3 16, Phase 2/3 5, Phase 2 52, Phase 1/2 22, Phase 1 36)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 213
2025 259
2024 222
2023 270
2022 229
2021 259
2020 241
2019 216
2018 203
2017 197

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 250 trials starting in 2026 and about 250 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 558 trials still running at the 2026-10-09 snapshot; registered median of 37 months across 2,488 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Urologic Neoplasms trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 771
Phase 1/2 374
Phase 2 1,125
Phase 2/3 34
Phase 3 312
Phase 4 72
Not applicable 727
Observational 902
Expanded access 16

How many Urologic Neoplasms trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 161
Recruiting 685
Enrolling by invitation 20
Active, not recruiting 346
Available 4

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Urologic Neoplasms trials? (10)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 231
Pfizer 91
Bristol-Myers Squibb 45
Merck Sharp & Dohme LLC 42
Novartis Pharmaceuticals 40

Showing 5 of 10 sponsors.

Start your 14-day trial Email me all 10 sponsors as a PDF

Which drugs are being tested for Urologic Neoplasms? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEMBROLIZUMAB 189
NIVOLUMAB 161
Sorafenib 82
EVEROLIMUS 69
IPILIMUMAB 68

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Gemcitabine/Gemzar 173
Sunitinib 4/2 144
Cisplatin 1 109
Bevacizumab 1 79
Pazopanib Pill 63

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Urologic Neoplasms trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,288 184
Urinary tract infection 998 158
Fatigue 995 190
Disease progression 982 73
Malignant neoplasm progression 955 56

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Urologic Neoplasms? (210)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial. Annals of oncology : official journal of the European Society for Medical Oncology 2026 Yes
Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence. International journal of biological sciences 2025 Yes
Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials. Clinical genitourinary cancer 2025 Yes
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. The New England journal of medicine 2025 Yes
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. The New England journal of medicine 2025 Yes

Showing 5 of 210 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages